Organon & Co. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
Organon & Co. (OGN) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-24
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2021-12-31 was -$14.00M.
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2021-09-30 was $0.00.
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2021-06-30 was $0.00.
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2021-03-31 was $29.00M.
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $27.00M, a 285.71% increase from fiscal 2023.
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $7.00M, a 41.67% decline from fiscal 2022.
- Organon & Co. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $12.00M, a 20.00% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 3 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 6 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 9 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $27.00M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $7.00M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $12.00M 10-K/A · filed 2025-11-10 | |||
| 2021-12-31 | -$14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$14.00M derived: sum of 2 quarters · filed 2024-02-26 | -$14.00M derived: sum of 3 quarters · filed 2024-02-26 | $15.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 derived: sum of 2 quarters · filed 2022-11-04 | $29.00M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $29.00M 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $29.00M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $19.00M 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $140.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |